Abstract:Abstract Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance. The genes that associated with cisplatin resistance remain unclear. Herein, we aimed to identify the cisplatin resistance associated genes in BUC. Experimental design The cytotoxicity of cisplatin was evaluated in six bladder cancer cell lines to compare their responses to cisplatin. The T24 cancer cells exhibited the lowest sensitivity to cisplatin and was therefore selected to explore the mechanisms of drug resistance. We performed genome-wide CRISPR screening in T24 cancer cells in vitro, and identified that the gene heterogeneous nuclear ribonucleoprotein U (HNRNPU) was the top candidate gene related to cisplatin resistance. Epigenetic and transcriptional profiles of HNRNPU-depleted cells after cisplatin treatment were analyzed to investigate the relationship between HNRNPU and cisplatin resistance. In vivo experiments were also performed to demonstrate the function of HNRNPU depletion in cisplatin sensitivity. Results Significant correlation was found between HNRNPU expression level and sensitivity to cisplatin in bladder cancer cell lines. In the high HNRNPU expressing T24 cancer cells, knockout of HNRNPU inhibited cell proliferation, invasion, and migration. In addition, loss of HNRNPU promoted apoptosis and S-phase arrest in the T24 cells treated with cisplatin. Data from The Cancer Genome Atlas (TCGA) demonstrated that HNRNPU expression was significantly higher in tumor tissues than in normal tissues. High HNRNPU level was negatively correlated with patient survival. Transcriptomic profiling analysis showed that knockout of HNRNPU enhanced cisplatin sensitivity by regulating DNA damage repair genes. Furthermore, it was found that HNRNPU regulates chemosensitivity by affecting the expression of neurofibromin 1 (NF1). Conclusions Our study demonstrated that HNRNPU expression is associated with cisplatin sensitivity in bladder urothelial carcinoma cells. Inhibition of HNRNPU could be a potential therapy for cisplatin-resistant bladder cancer.

Supplementary Figures from A PolH Transcript with a Short 3′UTR Enhances PolH Expression and Mediates Cisplatin Resistance

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

Supplementary Figure S7 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Supplementary Figure S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Supplementary Figure S5 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Supplementary Tables from NAT10 Drives Cisplatin Chemoresistance by Enhancing Ac4c-Associated DNA Repair in Bladder Cancer

CPSF6-mediated XBP1 3'UTR Shortening Attenuates Cisplatin-Induced ER Stress and Elevates Chemo-Resistance in Lung Adenocarcinoma.

Co-inhibition of Pol Θ and HR Genes Efficiently Synergize with Cisplatin to Suppress Cisplatin-Resistant Lung Cancer Cells Survival

Supplementary Figure S1 from the Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating <i>laptm4b</i> Expression

OTT_A_223321 657..666

&Lt;p>zfas1 Promotes Cisplatin Resistance Via Suppressing Mir-421 Expression in Oral Squamous Cell Carcinoma</p>

Mir-324-3p Reverses Cisplatin Resistance by Inducing GPX4-mediated Ferroptosis in Lung Adenocarcinoma Cell Line A549

Supplementary Figure 4 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

SNHG14 Stimulates Cell Autophagy to Facilitate Cisplatin Resistance of Colorectal Cancer by Regulating Mir-186/Atg14 Axis.

SNHG15 Contributes To Cisplatin Resistance In Breast Cancer Through Sponging miR-381

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

Supplementary Tables (S1-S2) from Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer Via Activation of Mir-126-5p/β-catenin/cbp Signaling

ISG15 Silencing Increases Cisplatin Resistance Via Activating P53-Mediated Cell DNA Repair

The DNA Methylation-Regulated Mir-193A-3p Dictates the Multi-Chemoresistance of Bladder Cancer Via Repression of SRSF2/PLAU/HIC2 Expression